Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 9/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.44 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.40 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | FES | P07332 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210662 | 0.93 | FGFR2 (0.45) | FGFR2KDRGAKRIPK2COQ8A | |
| SCHEMBL2208494 | 0.89 | MAPT (0.54) | FGFR2KDRHTT | |
| SCHEMBL2213005 | 0.87 | IKBKB (0.46) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2209486 | 0.87 | FGFR2 (0.48) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2211970 | 0.85 | AURKA (0.48) | FGFR2KDRHTTAURKAAURKB | |
| SCHEMBL2210453 | 0.85 | FGFR2 (0.44) | FGFR2KDRGAKRIPK2COQ8A | |
| SCHEMBL3732592 | 0.85 | FGFR2 (0.42) | FGFR2KDRGAKRIPK2COQ8A | |
| SCHEMBL2210693 | 0.84 | AURKA (0.54) | FGFR2KDRGAKRIPK2COQ8A | |
| SCHEMBL2208492 | 0.84 | KDR (0.46) | FGFR2KDRMAPKAPK2 | |
| SCHEMBL2208733 | 0.83 | FGFR2 (0.41) | FGFR2KDRGAKRIPK2COQ8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | claimed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | claimed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | FGFR2 334/4885KDR 644/4885GAK 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.